Paclitaxel Poliglumex (OPAXIO(TM))/Capecitabine Regimen Well Tolerated And Active In

[News]

At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (OPAXIO(TM), CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC). The goals of the study were to explore the tolerability and objective anti-tumor response rate as well as the disease-free progression and survival times of the regimen.

More... (http://www.medicalnewstoday.com/articles/109810.php)